Guest Editor(s)

• Dr. Charles Dumontet

  Hospices Civils de Lyon, Lyon, France.

  Website | E-mail

Special Issue Introduction

Immune checkpoint inhibitors have provided prolonged remission in a minority of patients with cancer, suggesting that most patients present with treatment-resistant disease, while responding patients will ultimately develop acquired resistance. In this special Issue we intend to address the biological, preclinical and clinical data currently available to better understand these phenomena, including molecular mechanisms and potential biomarkers of resistance. The second aim is to describe therapeutic options in patients with resistance to immune checkpoint inhibitors, including but not limited to therapeutic combinations and alternative immune checkpoint targeting. This issue will welcome both original articles, reviews, perspectives, case reports and will be of great interest for all physicians dealing with cancer patients.

Submission Deadline

20 Mar 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/CDR/?IssueId=496
Submission Deadline: 20 Mar 2021
Contacts: Chloe Yang, Assistant Editor, chloe@cdrjournal.com